Tryptamine Therapeutics Ltd
TYP
Company Profile
Business description
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Contact
C/o Bio101 Financial Advisory Pty Ltd
697 Burke Road, Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920475
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
50
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,369.30 | 4.70 | -0.06% |
| CAC 40 | 7,713.91 | 14.02 | -0.18% |
| DAX 40 | 23,213.42 | 131.12 | -0.56% |
| Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
| FTSE 100 | 8,599.50 | 3.15 | 0.04% |
| HKSE | 22,662.71 | 158.03 | 0.70% |
| NASDAQ | 17,844.24 | 133.49 | -0.74% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.09 | 0.16 | -0.00% |
| S&P 500 | 5,650.38 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,151.40 | 6.40 | -0.08% |
| SSE Composite Index | 3,316.11 | 37.08 | 1.13% |